PKC - A target for treating diabetic complications
Author:
- 1 January 2006
- journal article
- review article
- Published by Portico in Drugs of the Future
- Vol. 31 (6) , 0503-511
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- The protein kinase C-β inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complicationsExpert Opinion on Investigational Drugs, 2005
- Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapyMuscle & Nerve, 2005
- Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trialClinical Therapeutics, 2005
- Importance of chroman ring and tyrosine phosphorylation in the subtype‐specific translocation and activation of diacylglycerol kinase α by d‐α‐tocopherolGenes to Cells, 2005
- Novel protein kinase C‐β isoform selective inhibitor JTT‐010 ameliorates both hyper‐ and hypoalgesia in streptozotocin‐ induced diabetic ratsDiabetes, Obesity and Metabolism, 2004
- PPARγ Agonists Ameliorate Endothelial Cell Activation via Inhibition of Diacylglycerol–Protein Kinase C Signaling PathwayCirculation Research, 2004
- Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathyNature Medicine, 2003
- Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy.Diabetes, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells.Diabetes, 1998